Catalyst Pharmaceuticals, Inc. (CPRX)Healthcare | Biotechnology | Coral Gables, United States | NasdaqCM
26.07 USD
-0.19
(-0.724%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★★★ | Long-term: ★★★★★ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 6:36 p.m. EDT
CPRX is a dual-conviction buy: a deep value stock with a massive earnings expansion catalyst and a high-conviction short-term momentum play. Fundamentally, the stock trades at a deep discount to its potential (Forward P/E ~8.4x) with an aggressive analyst rating mean (34.0), while the chart shows a confirmed breakout above 200-day support. Technically, the options flow confirms aggressive buying of upside at higher strikes, targeting a move past the all-time high of 26.58. The lack of dividends is irrelevant given the exceptional growth and undervaluation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.034068 |
| AutoTheta | 0.034506 |
| AutoARIMA | 0.040515 |
| AutoETS | 0.042245 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 64% |
| H-stat | 1.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.236 |
| Excess Kurtosis | 0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.292 |
| Revenue per Share | 4.816 |
| Market Cap | 3,204,325,888 |
| Trailing P/E | 15.52 |
| Forward P/E | 8.37 |
| Beta | 0.66 |
| Profit Margins | 36.39% |
| Website | https://catalystpharma.com |
As of April 19, 2026, 6:36 p.m. EDT: Options architecture is heavily skewed bullish. Calls show significantly higher volume and Open Interest (OI) at out-of-the-money strikes (30.0) compared to puts, suggesting leverage-heavy betting on upside momentum. While puts have substantial OI at lower strikes (20.0-22.5) indicating a floor, the ratio of call to put volume is extremely high, especially on the 6-month horizon where OTM call OI dominates. Implied volatility is moderate (0.50-0.75 range), implying a fair-priced environment without excessive fear premiums that would deter a long entry.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.15353978 |
| Address1 | 355 Alhambra Circle |
| Address2 | Suite 801 |
| All Time High | 26.58 |
| All Time Low | 0.37 |
| Ask | 26.13 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,527,570 |
| Average Daily Volume3 Month | 1,250,059 |
| Average Volume | 1,250,059 |
| Average Volume10Days | 1,527,570 |
| Beta | 0.664 |
| Bid | 26.02 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 7.789 |
| City | Coral Gables |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.07 |
| Current Ratio | 6.076 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 26.42 |
| Day Low | 25.89 |
| Debt To Equity | 0.292 |
| Display Name | Catalyst Pharmaceuticals |
| Earnings Call Timestamp End | 1,772,112,600 |
| Earnings Call Timestamp Start | 1,772,112,600 |
| Earnings Growth | -0.064 |
| Earnings Quarterly Growth | -0.058 |
| Earnings Timestamp | 1,772,053,200 |
| Earnings Timestamp End | 1,778,097,600 |
| Earnings Timestamp Start | 1,778,097,600 |
| Ebitda | 295,651,008 |
| Ebitda Margins | 0.50196 |
| Enterprise To Ebitda | 8.379 |
| Enterprise To Revenue | 4.206 |
| Enterprise Value | 2,477,385,728 |
| Eps Current Year | 2.85163 |
| Eps Forward | 3.11554 |
| Eps Trailing Twelve Months | 1.68 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 24.346 |
| Fifty Day Average Change | 1.723999 |
| Fifty Day Average Change Percent | 0.07081241 |
| Fifty Two Week Change Percent | 15.353977 |
| Fifty Two Week High | 26.58 |
| Fifty Two Week High Change | -0.5100002 |
| Fifty Two Week High Change Percent | -0.019187368 |
| Fifty Two Week Low | 19.05 |
| Fifty Two Week Low Change | 7.0200005 |
| Fifty Two Week Low Change Percent | 0.368504 |
| Fifty Two Week Range | 19.05 - 26.58 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,162,996,200,000 |
| Float Shares | 114,525,336 |
| Forward Eps | 3.11554 |
| Forward P E | 8.367731 |
| Free Cashflow | 171,340,256 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 182 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.83028 |
| Gross Profits | 489,027,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06185 |
| Held Percent Institutions | 0.89205 |
| Implied Shares Outstanding | 122,912,388 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. |
| Long Name | Catalyst Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 3,204,325,888 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_5103575 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 214,326,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,183,769,655 |
| Number Of Analyst Opinions | 7 |
| Open | 26.26 |
| Operating Cashflow | 208,670,000 |
| Operating Margins | 0.40525 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 305 420 3200 |
| Pre Market Change | -0.21999931 |
| Pre Market Change Percent | -0.8438792 |
| Pre Market Price | 25.85 |
| Pre Market Time | 1,776,777,252 |
| Previous Close | 26.26 |
| Price Eps Current Year | 9.142139 |
| Price Hint | 2 |
| Price To Book | 3.3470278 |
| Price To Sales Trailing12 Months | 5.4403834 |
| Profit Margins | 0.36389 |
| Quick Ratio | 5.691 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.190001 |
| Regular Market Change Percent | -0.723536 |
| Regular Market Day High | 26.42 |
| Regular Market Day Low | 25.89 |
| Regular Market Day Range | 25.89 - 26.42 |
| Regular Market Open | 26.26 |
| Regular Market Previous Close | 26.26 |
| Regular Market Price | 26.07 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 1,473,964 |
| Return On Assets | 0.16479 |
| Return On Equity | 0.25486 |
| Revenue Growth | 0.076 |
| Revenue Per Share | 4.816 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 122,123,884 |
| Shares Percent Shares Out | 0.0748 |
| Shares Short | 9,132,015 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 9,286,059 |
| Short Name | Catalyst Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0956 |
| Short Ratio | 7.67 |
| Source Interval | 15 |
| State | FL |
| Symbol | CPRX |
| Target High Price | 36.0 |
| Target Low Price | 32.0 |
| Target Mean Price | 34.0 |
| Target Median Price | 35.0 |
| Total Cash | 709,171,008 |
| Total Cash Per Share | 5.807 |
| Total Debt | 2,787,000 |
| Total Revenue | 588,988,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.68 |
| Trailing P E | 15.517858 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 22.41675 |
| Two Hundred Day Average Change | 3.6532497 |
| Two Hundred Day Average Change Percent | 0.16296965 |
| Type Disp | Equity |
| Volume | 1,473,964 |
| Website | https://catalystpharma.com |
| Zip | 33,134 |